Associated Papers
Association of TERT promoter mutation with oral squamous cell carcinoma: a systematic review and meta-analysis.
Yuwanati M et al.
Scientific Reports, 2025
TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up.
Abi-Raad R et al.
American Journal of Clinical Pathology, 2025
The impact of C216T and hot spot mutations of the TERT promoter on the clinicopathologic characteristics and S100A10 expression in papillary thyroid carcinoma: a comparative study.
Li P et al.
Diagnostic Pathology, 2025
Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population.
Hwang I et al.
Pathology, Research and Practice, 2025
Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma.
Chao A et al.
Bmc Cancer, 2024
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Nakauma-González JA et al.
Cell Genomics, 2024
Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK et al.
Scientific Reports, 2023
Genetic characteristics of advanced oral tongue squamous cell carcinoma in young patients.
Kim S et al.
Oral Oncology, 2023
Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.
Yeh TJ et al.
Biomedicines, 2023
Identification of h-TERT Promoter Mutations in Germline DNA from North Indian Lung Carcinoma Patients.
Prasad R et al.
Indian Journal of Clinical Biochemistry : Ijcb, 2023
Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Zvereva M et al.
Methods in Molecular Biology (clifton, N.j.), 2023
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.
Kuhn CK et al.
Plos One, 2023
Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis.
Zhang D et al.
The European Respiratory Journal, 2022
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients.
Yang H et al.
Endocrinology and Metabolism (seoul, Korea), 2022
PROBER identifies proteins associated with programmable sequence-specific DNA in living cells.
Mondal S et al.
Nature Methods, 2022
Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances.
Hasanau T et al.
Biomedicines, 2022
Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers.
Kang SY et al.
Bmc Medical Genomics, 2022
Evaluation of NAB2-STAT6 Fusion Variants and Other Molecular Alterations as Prognostic Biomarkers in a Case Series of 83 Solitary Fibrous Tumors.
Salguero-Aranda C et al.
Cancers, 2021
IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
Crezee T et al.
Oncology Letters, 2021
TERT promoter mutation in patients with second primary of tongue squamous cell carcinoma.
Erkul E et al.
Oral Oncology, 2021
Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer.
Hosen MI et al.
Cancers, 2020
Clinical and mutational profiles of adult medulloblastoma groups.
Wong GC et al.
Acta Neuropathologica Communications, 2020
Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer.
Zvereva M et al.
International Journal of Molecular Sciences, 2020
Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Stögbauer L et al.
Neurosurgical Review, 2020
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.
Sjödahl G et al.
International Journal of Cancer, 2020
Genetic profile of advanced thyroid cancers in relation to distant metastasis.
Song E et al.
Endocrine-related Cancer, 2020
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI et al.
Ebiomedicine, 2020
Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma.
Geng J et al.
Science China. Life Sciences, 2019
Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH et al.
Ebiomedicine, 2019
Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival.
Mundi N et al.
Cancers of the Head & Neck, 2019
Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS et al.
European Urology Focus, 2018
TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S et al.
Neuro-oncology, 2018
Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN et al.
Head & Neck, 2018
Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Deng MY et al.
Acta Neuropathologica, 2018
Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP et al.
Head & Neck, 2017
The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Lee J et al.
Journal of Neuro-oncology, 2017
A six-genotype genetic prognostic model for papillary thyroid cancer.
Shen X et al.
Endocrine-related Cancer, 2017
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA et al.
Genome Medicine, 2016
TERT promoter mutations and monoallelic activation of TERT in cancer.
Huang FW et al.
Oncogenesis, 2015
Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS et al.
European Journal of Cancer (oxford, England : 1990), 2015
When thyroid carcinoma goes bad: a morphological and molecular analysis.
Papp S et al.
Head and Neck Pathology, 2015
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K et al.
Oncotarget, 2014
Recurrent TERT promoter mutations in non-small cell lung cancers.
Ma X et al.
Lung Cancer (amsterdam, Netherlands), 2014
Integrated genomic characterization of papillary thyroid carcinoma.
Unknown Author
Cell, 2014